SCHEMBL5459988

SCHEMBL5459988

NC(=O)c1c(NC(=O)Nc2cc(C(F)(F)F)ccc2Cl)sc2c1CCOC2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANO1 Q5XXA6 4/20 0.53
CFTR P13569 1/20 0.51
CHRNA7 P36544 1/20 0.47
MAPT P10636 2/20 0.45
TP53 P04637 1/20 0.45
GAA P10253 1/20 0.45
KCNH2 Q12809 2/20 0.44
CNR2 P34972 7/20 0.44
CNR1 P21554 4/20 0.44
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
ATM Q13315 1/20 0.43
USP36 Q9P275 1/20 0.42
MET P08581 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5447615 0.87 FLT3 (0.56) ANO1CFTRCHRNA7MAPTPOLB
SCHEMBL5450945 0.85 CFTR (0.54) ANO1CFTRKCNH2CNR2CNR1
SCHEMBL5447523 0.84 CFTR (0.56) ANO1CFTRKCNH2CNR2CNR1
SCHEMBL5450655 0.84 CFTR (0.54) ANO1CFTRKCNH2CNR2CNR1
SCHEMBL5451368 0.84 CHRNA7 (0.47) CFTRCHRNA7MAPTTP53GAA
SCHEMBL5460654 0.83 ANO1 (0.64) ANO1CFTRKCNH2CNR2CNR1
SCHEMBL5460167 0.83 KDR (0.60) ANO1CFTRMAPTKCNH2CNR2
SCHEMBL5453563 0.83 CFTR (0.52) ANO1CFTRMAPTKCNH2CNR2
SCHEMBL5454317 0.81 MEN1 (0.63) ANO1CFTRMAPTKCNH2CNR2
SCHEMBL5457877 0.80 CFTR (0.57) ANO1CFTRMAPTKCNH2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 ANO1 3245/4885CFTR 2030/4885CHRNA7 669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.